THE COMPANY
The Company
The Company
AEQPharma is a biotechnology R&D, manufacturing, and sales of mAbs and exosome-based therapeutics derived from human cells.
Our Purpose
To contribute to the creation of a healthier society by providing innovative solutions using pharmaceutical-grade exosomes to address unmet health challenges.
Our current pipeline consists of severals biosimilars and several monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases.
We develop, produce and release our APIs and biosimilars in house with the latest available technology and to the highest quality standards for the supply of finished and ready to commercialize products worldwide.
Aequilibrium Pharma is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. Our core values are life-improvement, collaboration, innovation and novel therapy.
OUR VISON & MISSION
OUR VISON & MISSION
Our Vision
To become a company that continuously creates solutions globally to meet unmet medical needs, by leveraging our exosome drug discovery technology built on cutting-edge science.
Our company's competitive advantages are our extensive data on exosome manufacturing and analysis, and our drug discovery expertise from an experienced R&D team with pharmaceutical industry background. We are committed to developing exosome-based drug discovery platform technologies that harness the scientific properties of exosomes, and to pursuing drug discovery using this platform.
OUR Mission IS TO ASSIST AND IMPROVE PATIENTS' LIVES BY DEVELOPING TARGETED THERAPEUTICS BASED ON SCIENTIFIC UNDERSTANDINGS OF IMMUNOLOGY, CANCER AND NEURODEGENERATIVE DISEASES.
We are focused on the rapid development and production of specialty drugs using our poprietary manufacturing platform based.
The company’s technology uses modified plants to produce biopharmaceuticals in fully contained greenhouse environments. Aequilibrium plant-based technology delivers high drug expression levels and mammalian-type glycosylation (to eliminate the risk of an unwanted immune system reaction) also provides key advantages compared to other fermentation systems for biologic drug production (e.g., Ibridomi, mammalian cell culture).
BIOLOGICAL PRODUCTION PROCESS
BIOLOGICAL PRODUCTION PROCESS
MOLECULES DEVELOPMENT
Determination of amino acid sequence and target profile of RMP
Cloning of synthetic target sequence into high-titter expression vector (gene of interest)
Transfection of Host cell line + single clone Preparation + Stability Assessment of Lead clone clone
Upstream and Downstream Process Development ( USP & DSP)
CELL BANKING (RCB)
Technology Transfer to production site (CDMO)
cGMP to production site (CMO)
The Energy
The Energy
A distuptive Biopharming
The element of innovation is the development of a proprietary technological and process platform for the production of recombinant biological active molecules (MAbs, IL, VLP ...) through a "Vertical Pharming" (cultivation of plants in a Hydrophonic vertical greenhouses ).
Aeuilibrium pharma has created a scientific network of excellence, collaborating with important national and international research institutions.
